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Available online 3 April 2016Background: Bipolar disorder (BD) is a severe and debilitating psychiatric disorder. However, the precise biolog-
ical basis remains unknown, hampering the search for novel biomarkers.We performed ametabolomics analysis
to discover novel peripheral biomarkers for BD.
Methods:We quantiﬁed serum levels of 116 metabolites in mood-stabilizedmale BD patients (n= 54) and age-
matched male healthy controls (n = 39).
Results: After multivariate logistic regression, serum levels of pyruvate, N-acetylglutamic acid, α-ketoglutarate,
and arginine were signiﬁcantly higher in BD patients than in healthy controls. Conversely, serum levels of β-
alanine, and serine were signiﬁcantly lower in BD patients than in healthy controls. Chronic (4-weeks) adminis-
tration of lithium or valproic acid to adult male rats did not alter serum levels of pyruvate, N-acetylglutamic acid,
β-alanine, serine, or arginine, but lithium administration signiﬁcantly increased serum levels ofα-ketoglutarate.
Conclusions: Themetabolomics analysis demonstrated altered serum levels of pyruvate,N-acetylglutamic acid,β-
alanine, serine, and arginine in BD patients.
General signiﬁcance: The present ﬁndings suggest that abnormalities in the citric acid cycle, urea cycle, and amino
acid metabolism play a role in the pathogenesis of BD.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Arginine1. Introduction
Bipolar disorder (BD) is a chronic mental illness characterized by re-
current episodes of depression, mania, and hypomania. Worldwide, the
combined lifetime prevalence of BD I and II is estimated between 1 and
3% [1]. People with BD are more prone to seek care when they are de-
pressed than when experiencing mania or hypomania. The condition
might therefore mistakenly be diagnosed as major depression and BD
patients are frequently treated with antidepressants in primary care
[2]. This is a problem because monotherapy with antidepressants in-
crease the risk of switch to mania in BD [3] and might sometimescience, Chiba University Center
0, Japan.
imoto).
to this work.
. This is an open access article underworsen symptoms [4,5]. Treatment guidelines therefore recommend
antidepressants only as adjunct therapy tomood stabilizers [6,7]. Misdi-
agnosiswill thus prevent BDpatients from receiving the correctmedica-
tion, and risk worsening the outcome. Biomarkers for aiding the
diagnosis of BD are therefore warranted.
Although the precise pathogenesis of BD is not well understood, ac-
cumulating evidence suggests that inﬂammation [8–10], mitochondrial
dysfunction, and oxidative stress [11–19] play a role in the pathogenesis
of BD. In addition, brain-derived neurotrophic factor (BDNF) and its pre-
cursor proBDNF, have been suggested as peripheral biomarkers for BD
[17,20–25]. Recently, we also reported that serum levels of glutamine,
glycine, and D-serine were signiﬁcantly higher in BD patients than in
healthy controls, whereas serum levels of L-serine were signiﬁcantly
lower in BD patients than in healthy controls [26]. However, we did
not ﬁnd alterations in these amino acids in cerebrospinal ﬂuid (CSF)
from the same BD patients [26]. The discrepancy between blood and
CSF highlights the importance to measure a potential biomarker inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to collect blood samples.
Metabolomics is theproﬁling of smallmoleculemetabolites andpro-
vides the potential to characterize speciﬁcmetabolic phenotypes associ-
atedwith a disease.Metabolomics has the advantage over other “omics”
techniques in that it directly samples the metabolic changes in an or-
ganism and integrates information from changes at the gene, transcript,
and protein level, as well as posttranslational modiﬁcations [27–29].
Metabolomics analysis with capillary electrophoresis time-of-ﬂight
mass spectrometry (CE-TOFMS) [30] has been used in the discovery of
biomarkers for psychiatric disorders, including BD [31], schizophrenia
[32], and autism spectrum disorder (ASD) [33]. We recently found
that CSF levels of isocitrate were signiﬁcantly higher in BD patients
than in healthy controls, and that the expression of isocitrate dehydro-
genase (IDH3A) mRNA and protein were signiﬁcantly lower in post-
mortem brain tissue from BD patients than in control samples [31].
These ﬁndings suggested that abnormal mitochondrial metabolism of
isocitrate by IDH3Aplays a key role in the pathogenesis of BD [31]. How-
ever, there are no corresponding metabolomics analyses of serum from
BD patients and healthy controls.
Here, we performed a metabolomics analysis using CE-TOFMS of
serum samples from mood-stabilized BD patients (n = 54) and age-
matched healthy controls (n = 39) [31]. We selected 116 major meta-
bolic compounds from the following pathways for metabolomics analy-
sis: the glycolytic system, the pentose phosphate pathway, the citric
acid cycle, the urea cycle, the polyamine-creatine metabolism pathway,
the purine metabolism pathway, the glutathione metabolism pathway,
the nicotinamide metabolism pathway, the choline metabolism path-
way and several amino acid metabolism pathways (Supplemental
Table 1). To examine potential effects of medication on the studied me-
tabolites, we also performed a metabolomics analysis of serum samples
from rats chronically treated with lithium (Li) or valproic acid (VPA).
2. Methods and Materials
2.1. Participants
The BD patients were recruited from the St. Göran bipolar project,
enrolling patients from the bipolar unit at the Northern Stockholm Psy-
chiatric Clinic, Stockholm, Sweden. The work-up and diagnostic assess-
ments have been described in detail previously [26,34,35]. The key
clinical assessment instrument was the Affective Disorder Evaluation
(ADE), developed for the Systematic Treatment Enhancement Program
of Bipolar Disorder (STEP-BD) [36]. The full diagnostic assessment was
based on all available sources of information including patient inter-
view, case records, and if possible interviewswith the next of kin. To re-
duce inter-rater bias, a best-estimate diagnostic decision based on all
information available at admission was made at a diagnostic case-
conference by a consensus panel of experienced board certiﬁed psychi-
atrists (n = 2–5) specialized in BD.
The general criteria for inclusionwere: 1) age of at least 18 years and
2) meeting the Diagnostic and Statistical Manual (DSM)-IV criteria for
bipolar spectrum disorder (i.e., type I, type II, or not otherwise speci-
ﬁed). Information regarding age, sex, number of lifetime manic/hypo-
manic/depressive/total episodes, duration of illness (deﬁned as years
since the ﬁrst hypomanic or manic episode), body mass index (BMI),
and previous psychotic episodes was collected. The severity of BD was
rated using the Clinical Global Impression (CGI) and Global Assessment
of Functioning (GAF) rating scales. For ethical reasons, patients contin-
ued to take their prescribedmedications at the time of serum sampling.
Population-based controls were randomly selected by Statistics
Sweden (SCB) and contacted by mail. Given an expected response rate
of 1:7, seven invitations were sent out per enrolled case. Fourteen per-
cent of the invited controls responded to the invitation, and were sub-
jected to a preliminary telephone screening by a research nurse to
exclude severe mental health conditions, neurological diseases, andsubstance abuse. Eligible persons were scheduled for a one-day com-
prehensive assessment where they underwent further psychiatric
interviewing by experienced clinicians using the Mini-International
Neuropsychiatric Interview (M.I.N.I.) to exclude psychiatric disorders
[37]. Substance abuse was screened for at the telephone interview by
the nurse, in the psychiatric interview, by the Alcohol Use Disorders
Identiﬁcation Test (AUDIT), and by the Drug Use Disorders Identiﬁca-
tion Test (DUDIT), as well as by determining serum levels of
carbohydrate-deﬁcient transferrin (CDT) [38]. Overconsumption of al-
cohol as revealed by CDT or responses indicating large consumption
(N8 standard drinks per timemore than 2 times per week), and/or am-
nesia and/or loss of control more than once per month resulted in the
exclusion of these individuals from the study. Other exclusion criteria
were neurological conditions other than mild migraines, untreated en-
docrinological disorders, pregnancy, dementia, recurrent depressive
disorder, and suspected severe personality disorders (based on inter-
view and the Structured Clinical Interview for DSM (SCID-II) screen per-
sonality assessment), as well as a family history of schizophrenia or BD
in ﬁrst-degree relatives.
The study was approved by the Regional Ethics Committee in
Stockholm and conducted in accordance with the latest Helsinki Proto-
col. All patients and controls consented orally and in writing to partici-
pate in the study. Informed consent was obtained during a euthymic
period (i.e., during a time period when patients did not meet criteria
for a depressive, hypomanic, or manic episode). All patients were capa-
ble of freely giving fully informed consent, as determined by the physi-
cians who enrolled the patient. A total of 54 male BD patients and 39
male healthy controls were included (Table 1).
2.2. Serum sampling
Serum samples were collected from fasting subjects between 8:00
and 9:00 am. The samples were centrifuged on site and stored at –
80 °C pending analysis at the Biobank at Karolinska Institutet,
Stockholm, Sweden. An identical procedure was performed for the con-
trols. The samples were stored at –80 °C until delivered by courier mail,
frozen on dry ice, to Chiba University (Japan) formetabolomics analysis.
This study was also approved by the Research Ethics Committee of the
Graduate School of Medicine (Chiba University).
2.3. Metabolomics analysis of human serum samples
Metabolomics analyses of serum samples from healthy controls and
BD patients were performed using the CE-TOFMS at Human Metabo-
lome Technologies (Yamagata, Japan). The sampled volume of 50 μL
was added to 450 μL methanol containing internal standards, and
mixed. Then, 450 μL chloroform and 200 μL Milli-Q water was added
to the mixture. The mixture was centrifuged at 2,300 ×g and 4 °C for
5min. Subsequently, 800 μL of upper aqueous layerwas centrifugally ﬁl-
tered through a Millipore 5-kDa cutoff ﬁlter at 9100 ×g and 4 °C for
120min to remove proteins. The ﬁltrate was centrifugally concentrated
and re-suspended in 25 μL of Milli-Q water for analysis.
Cationic compounds were measured in the positive mode of CE-
TOFMS (Agilent CE-TOFMS systemMachine No. 3, Fused silica capillary,
i.d. 50 μM× 80 cm), and anionic compounds weremeasured in the pos-
itive and negative modes of CE-MS/MS (Agilent CE system and Agilent
6400 TripleQuad LC/MS Machine No. QqQ01, Fused silica capillary, i.d.
50 μM × 80 cm), as reported previously [39, 40]. Peaks detected by
CE-TOFMS and CE–MS/MS were extracted using automatic integration
software (MasterHands, Keio University, Tsuruoka, Japan) [41] and
MassHunter Quantitative Analysis B.04.00, Agilent Technologies, Santa
Clara, CA, USA) in order to obtain peak information including m/z, mi-
gration time (MT), and peak area. The peakswere annotated with puta-
tive metabolites from the HMTmetabolite database based on their MTs
in CE andm/z values determined by TOFMS. The tolerance range for the
peak annotation was conﬁgured at ±0.5 min for MT and ±10 ppm for
Table 1
Characteristics of the participants.
Controls BD Patients
Number (male) 39a 54
Median IQR Median IQR
Age (years) 36 29–47 41 32–52
BMI 24.1 22.8–25.8 25.7 24.1–28.1
Diagnosis N %
Bipolar disorder type I (BP I) 31 57.4
Bipolar disorder type II(BP II) 17 31.5
Not otherwise speciﬁed (NOS) 6 11.1
Clinical data Median IQR
Age ﬁrst symptoms 20 14–25
Depressive episodesc 6 3–10
Hypomanic episodesb 2 0–5
Manic episodesb 1 0–2
Mixed episodesb 0 0–25
GAFb 70 60–80
MADRSf 4 0–11
YMRSg 1 0–2
No of episodesb 18 1–80
Audit total scoree 8 2–11
Dudit total scored 0 0–0
N %
Psychosis episodesb 25 46.3
Family history of bipolara 26 49.1
Family history of unipolara 30 56.6
Alcohol dependencec 14 26.9
Alcohol abusec 13 25.0
Substance abusec 8 15.4
Medication N %
Mood stabilizer 44 81.5
Lithium (Li) 34 63.0
Anticonvulsants 19 35.2
Valproate (VPA) 7 13.0
Lamotrigine 12 22.2
Antidepressants 20 37.0
Anxiolytics 11 20.4
Antipsychotics 16 29.6
IQR: Interquartile Range.
GAF: Global Assessment of Functioning.
MADRS: Montgomery–Åsberg Depression Rating Scale.
YMRS: Young Mania Rating Scale.
a Missing data for 1 individual in the control group.
b Missing data for 1 individual in the patient group.
c Missing data for 2 individual in the patient group.
d Missing data for 6 individual in the patient group.
e Missing data for 9 individual in the patient group.
f Missing data for 10 individual in the patient group.
g Missing data for 11 individual in the patient group.
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malizing the peak area of eachmetabolitewith respect to the area of the
internal standard and byusing standard curves, whichwere obtained by
three-point calibrations. A total of 116 major metabolic substances on
various pathways (glycolytic system, pentose phosphate pathway, citric
acid cycle, urea cycle, polyamine–creatine metabolism pathway, purine
metabolism pathway, glutathione metabolism pathway, nicotinamide
metabolism pathway, choline metabolism pathway and diverse amino
acid metabolism pathway) were selected for metabolomics analysis
(Supplemental Table 1).
2.4. Statistical analyses
Data from human samples are presented as mean ± standard devi-
ation (SD). Statistical analyses were performed using SAS software ver-
sion 9.3 (SAS Institute, Cary, NC). Analyses of metabolites between
control and BD groups were performed using unpaired t-tests
(Table 1) and Wilcoxon rank sum tests (data not shown). In addition
we also performed multiple logistic and linear regression models with
a stepwise selection method [42,43]. Internal validation of the logistic
regression models was performed using the Hosmer–Lemeshowgoodness-of-ﬁt test, in which a p-value greater than 0.1 indicates a
good ﬁt [44], and the performance was evaluated by the jack-knife
method (a performance evaluation method in which a measured
value predicted from the n− 1 observations, removing the own pre-
dicted observation) [45]. False discovery rate was used to control for
multiple comparisons as indicated in the results [46] and P b 0.05 was
considered statistically signiﬁcant. Data from rat experiments are pre-
sented as mean ± SD. To determine the effects of drug treatment, a
one-way ANOVA, followed by the post hoc Dunnett's test was used. P-
values of less than 0.05 for two-tailed tests were considered statistically
signiﬁcant.
3. Results
3.1. Metabolomics of serum samples from BD patients and controls
Aswe previously reported [31], therewere nowdifferences between
the 39 healthy controls and the 54 BD patients in regard to age and BMI.
Out of the 116major metabolic substances measured, 82were detected
in serum, while the remaining 34 were under the detection limit
(Table 2). To selectmetabolites showing signiﬁcant differences between
BD patients and healthy controls, we ﬁrst performed both unpaired t-
tests and Wilcoxon rank sum tests between BD patients and healthy
controls. Eighteen compounds, including uric acid, CoA, glycerol 3-
phosphate, pyruvic acid (pyruvate), N-acetylglutamic acid (N-
acetylglutamate), 2-hydroxyglutaric acid, 2-oxoglutaric acid (α-
ketoglutarate), citric acid (citrate), cis-aconitic acid (cis-aconitate),
isocitric acid (isocitrate), urea, β-alanine, serine, valine, threonine, orni-
thine, glutamine, and argininewere altered (Table 2). Thesemetabolites
are molecules in the citric acid cycle, the urea cycle, and the amino acid
metabolism (Fig. 1).
Amultiple logistic regression analysiswas performed to evaluate the
association between these 18metabolites and BD. A stepwise selection-
elimination method was used, and the signiﬁcance level was set at 5%.
Six parameters – pyruvate, N-acetylglutamate, α-ketoglutarate, β-
alanine, serine, and arginine – were independently associated with BD
(Supplemental Table 2, and Table 3; see footnote for the resulting equa-
tion). In this model, after cross-validation testing using the jack-knife
procedure, the model's sensitivity was 85.2% and the speciﬁcity was
76.9%. The Hosmer–Lemeshow goodness-of-ﬁt statistic (the internal
validation of the logistic regression model) was 3.61 with 8 DF (P =
0.89), indicating a good ﬁt of the model (Fig. 2).
To investigate whether these six substances were associated with
clinical features or medication in BD patients, we performed additional
multiple linear regression analyses. The independent variables were:
age at ﬁrst symptoms, GAF score, total number of mood episodes (de-
pressive, hypomanic, manic and mixed), MADRS score, YMRS score,
AUDIT total score, DUDIT total score, psychotic episodes, family history
(e.g., bipolar and unipolar), alcohol dependence, alcohol use, substance
abuse, and medication (mood stabilizer, Li, anticonvulsant, VPA,
lamotrigine, antidepressant, anxiolytic, and antipsychotic). Results
demonstrated that a history of a manic episode (P = 0.009) and
YMRS (P = 0.013) were positively correlated with pyruvic acid. The
number of depressive episodes (P = 0.012) and Li medication (P =
0.002) were positively related with N-acetylglutamic acid, whereas al-
cohol dependence (P = 0.002) was negatively correlated with β-
alanine. Limedication (P=0.004)waspositively correlatedwith serine,
while anxiolytic medication (P = 0.001) and antipsychotic medication
(P = 0.011) were correlated with arginine. No variables were related
with α-ketoglutarate (Supplemental Table S3 and S4).
3.2. Effects of Li and VPA on rat serum levels
To examine the effects of medication on the metabolites, we per-
formed metabolomics analyses of serum samples from rats treated
with chronic (4-weeks) Li or VPA. We measured the serum
Table 2
Metabolomics data of human serum samples.
Compound name Concentration (μM) Comparative analysis
Controls BD patients P value
Mean S.D. N Mean S.D. N
Nicotinamide adenine dinucleotide (NAD+) 1.0 0.06 38 1.0 0.04 51 0.703
Cyclic AMP (cAMP) 0.008 0.007 38 0.007 0.004 52 0.871
Cyclic GMP (cGMP) 0.013 0.014 8 0.007 0.004 16 0.254
Xanthine 3.5 1.1 39 3.8 1.2 54 0.271
Mevalonic acid 0.03 0.02 8 0.05 0.05 18 0.063
UDP-glucose 0.4 0.03 24 0.4 0.014 21 0.445
Uric acid 339 46 39 368 66 54 0.014⁎
IMP 0.09 0.010 21 0.08 0.005 26 0.401
Oxidised nicotinamide adenine dinucleotide phosphate (NADP+) 0.10 0.015 11 0.10 0.004 16 0.396
Glucose 6-phosphate 0.2 0.05 39 0.2 0.06 53 0.321
Fructose 6-phosphate 0.05 0.02 37 0.06 0.02 45 0.421
Ribose 5-phosphate 0.03 N.A. 1 N.D. N.A. 0 N.A.
Acetoacetyl CoA 0.04 9.7E−04 5 0.04 1.2E−04 2 0.353
Acetyl CoA 0.02 0.03 3 0.002 0.003 3 0.450
Folic acid N.D. N.A. 0 0.03 6.0E−04 2 N.A.
CoA 0.3 0.002 2 0.3 0.004 5 0.049⁎
Ribose 1-phosphate 0.3 0.15 36 0.3 0.14 51 0.899
Ribulose 5-phosphate 0.10 0.02 14 0.11 0.013 16 0.302
Erythrose 4-phosphate 0.011 N.A. 1 0.011 N.A. 1 N.A.
Glyceraldehyde 3-phosphate N.D. N.A. 0 0.09 0.07 3 N.A.
Reduced nicotinamide adenine dinucleotide phosphate (NADPH) 0.7 0.008 2 0.7 0.02 7 0.686
Phosphocreatine 0.06 N.A. 1 N.D. N.A. 0 N.A.
Adenylosuccinic acid 0.05 0.005 8 0.05 0.002 13 0.554
Fructose 1,6-diphosphate 0.2 0.05 2 0.13 0.02 3 0.598
6-Phosphogluconic acid 0.3 N.A. 1 0.2 N.A. 1 N.A.
N-carbamoylaspartic acid 0.08 0.04 39 0.10 0.04 54 0.170
PRPP N.D. N.A. 0 0.03 1.3E−03 2 N.A.
2-Phosphoglyceric acid 0.03 0.03 6 0.02 0.02 9 0.958
3-Phosphoglyceric acid 0.2 0.08 39 0.2 0.11 53 0.471
2-Oxoisovaleric acid 14 2.5 39 14 2.8 54 0.507
GDP 0.3 0.03 11 0.3 0.010 18 0.860
Lactic acid 2,173 592 39 2,061 489 54 0.321
ADP 0.6 0.05 15 0.6 0.02 18 0.348
GTP 2.3 0.005 2 2.3 0.08 6 0.917
ATP 5.0 0.15 5 4.9 0.2 8 0.513
Glycerol 3-phosphate 1.8 0.5 39 1.6 0.5 54 0.074
Glycolic acid 8.2 1.6 39 8.4 1.8 51 0.554
Pyruvic acid 35 23 39 48 24 54 0.009⁎⁎
N-acetylglutamic acid 0.2 0.03 37 0.3 0.05 54 0.002⁎⁎
2-Hydroxyglutaric acid 0.6 0.2 39 0.7 0.3 54 0.046⁎
Succinic acid 6.2 1.0 39 6.1 1.1 54 0.954
Malic acid N.D. N.A. 0 1.9 2.1 2 N.A.
2-Oxoglutaric acid 4.0 2.2 39 8.7 5.5 54 b .0001⁎⁎⁎
Citric acid 92 21 39 73 20 54 b .0001⁎⁎⁎
cis-Aconitic acid 1.2 0.3 39 1.0 0.3 54 0.012⁎
Isocitric acid 4.2 1.1 39 3.8 1.2 54 0.057
Urea 5,623 1,145 39 4,955 1,039 54 0.004⁎⁎
Glycine (Gly) 360 50 39 359 54 54 0.947
Alanine (Ala) 449 79 39 475 76 54 0.121
Sarcosine 1.5 1.0 38 1.4 1.0 51 0.990
β-alanine (β-ala) 3.7 1.2 39 2.7 0.8 54 b .0001⁎⁎⁎
γ-Aminobutyric acid N.D. N.A. 0 0.2 0.07 6 N.A.
N,N-Dimethylglycine 3.5 1.7 39 3.5 2.0 54 0.998
Choline 13 4.2 39 12 3.8 54 0.366
Serine (Ser) 230 28 39 209 32 54 0.002⁎⁎
Creatinine 84 9.7 39 85 13 54 0.884
Proline (Pro) 268 89 39 278 121 54 0.653
Valine (Val) 340 40 39 324 45 54 0.084
Betaine 50 13 39 48 16 54 0.526
Threonine (Thr) 163 24 39 150 27 54 0.020⁎
Hydroxyproline 16 7.3 39 17 8.9 54 0.562
Creatine 31 16 39 34 13 54 0.265
Isoleucine (Ile) 82 12 39 83 17 54 0.760
Leucine (Leu) 187 20 39 184 25 54 0.424
Asparagine (Asn) 55 5.7 39 54 7.8 54 0.252
Ornithine 79 19 39 71 16 54 0.019⁎
Asparagic acid (Asp) 37 7.5 39 36 7.9 54 0.690
Hypoxanthine 10 3.0 39 10 2.8 54 0.966
Glutamine (Gln) 723 63 39 701 98 54 0.194
Lysine (Lys) 225 33 39 223 31 54 0.729
Glutamic acid (Glu) 103 27 39 122 40 54 0.006⁎⁎
Methionine (Met) 24 3.0 39 23 3.8 54 0.593
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Table 2 (continued)
Compound name Concentration (μM) Comparative analysis
Controls BD patients P value
Mean S.D. N Mean S.D. N
Histidine (His) 97 10 39 95 11 54 0.301
Carnitine 59 12 39 62 10 54 0.237
Phenylalanine (Phe) 87 10 39 87 13 54 0.990
Arginine (Arg) 122 19 39 131 23 54 0.039⁎
Citrulline 37 6.4 39 38 7.1 54 0.738
Thyosine (Tyr) 65 12 39 68 17 54 0.239
Triptophane (Trp) 72 9.3 39 71 14 54 0.737
Cystathionine 1.1 0.2 3 0.8 0.13 2 0.216
Inosine 3.2 1.2 11 4.5 2.2 13 0.087
Guanosine N.D. N.A. 0 1.4 0.3 5 N.A.
N.D.: Not Detected.
N.A.: Not Available.
Unpaired t-test or Wilcoxon rank sum t-test (*P b 0.05, **P b 0.01, ***P b 0.001)
P b 0.1
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lites were detected in the rat serum. Results showed that treatment
with Li signiﬁcantly increased serum levels of 2-hydroxyglutaric acid,
malic acid (malate), α-ketoglutarate, fumaric acid (fumarate), citrate,
and betaine. Treatment with VPA signiﬁcantly altered serum levels ofFig. 1.Metabolic pathway of the citric acid cycle, urea cycle, and amino acidmetabolism Amino
from other substances. Pyruvic acid (pyruvate) is prepared from glucose through glycolysis. Pyr
breakdown of sugars by glycolysis that yield pyruvate that in turn is decarboxylated by the enz
acid (TCA) cycle or the Krebs cycle) beginswith the transfer of a two-carbon acetyl group from a
(citrate). In the citric acid cycle,α-ketoglutarate is synthesized from isocitric acid (isocitrate) by
dependent dioxygenase (2-OGDO).N-acetylglutamic acid is synthesized from glutamic acid and
in the urea cycle, and plays a role in the production of nitric oxide (NO). β-alanine is synthesiz
carnosine. Substances in the dark box are signiﬁcantly altered in the serum from bipolar disordphosphocreatine, glycine,N,N-dimethylglycine, creatine, threonine, glu-
tamine, and tryptophan (Supplemental Table 5). Thus, serum levels of
pyruvate, N-acetylglutamic acid, α-ketoglutarate, β-alanine, serine,
and arginine in rats were not altered by chronic treatment with Li or
VPA (Supplemental Table 5).acid metabolism is biochemical processes by which the various amino acids are produced
uvate is metabolized to oxaloacetate by pyruvate carboxylase. Acetyl-CoA is also from the
yme pyruvate dehydrogenase (PDH). The citric acid cycle (also known as the tricarboxylic
cetyl CoA to the four-carbon acceptor substance oxaloacetate to form six-carbon substance
isocitrate dehydrogenase (IDH2/3), and ismetabolized to succinyl-CoA by 2-oxoglutarate-
acetyl-CoA byN-acetylglutamate synthase (NAGS). Arginine is synthesized from citrulline
ed from aspartate by aspartate 1-decarboxylase, and is also the rate-limiting precursor of
er (BD) patients.
Table 3
Independent predictor in serum samples of BD patients by logistic regression.
Parameter Odds ratio (95% conﬁdence interval) P value
Pyruvic acid 0.940 (0.896–0.987) 0.0128
N-acetylglutamic acid N999.999 (N999.999–N999.999) 0.0042
α-Ketoglutarate 1.683 (1.218–2.324) 0.0016
β-alanine 0.264 (0.109–0.638) 0.0031
Serine 0.947 (0.918–0.977) 0.0007
Arginine 1.045 (1.009–1.082) 0.0149
BD: Bipolar disorder
Logistic function, P = 1/{1 + exp (−1.0826 + 0.0614X1 − 40.1927X2 − 0.5203X3 +
1.3329X4 + 0.0544X5− 0.0436X6)}.
P: Probability of being statistically-discriminated as BD
X1, Pyruvic acid; X2, N-acetylglutamic acid; X3, α-Ketoglutarate; X4, β-alanine; X5, Ser-
ine; X6, Arginine
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This is the ﬁrst study showing increased serum levels of pyruvate,N-
acetylglutamic acid,α-ketoglutarate, and arginine, as well as decreased
serum levels ofβ-alanine in BDpatients comparedwith controls. Chron-
ic (4-weeks) treatment of Li or VPA did not alter serum levels of pyru-
vate, N-acetylglutamic acid, α-ketoglutarate, β-alanine, serine, or
arginine in rats, suggesting that themood stabilizers Li or VPA do not af-
fect the synthesis and metabolism of these substances in the blood.
Thus, it is unlikely that the use of thesemood stabilizers explain altered
serum levels of thesemetabolites in BD patients, although somemetab-
olites were associated with clinical variables and medications.
Accumulating evidence supports that mitochondrial dysfunction
plays a key role in the pathogenesis of BD [11–18]. Pyruvate, the end-
product of glycolysis, is derived from additional sources in the cellular
cytoplasm (Fig. 1), and is ultimately destined for transport into mito-
chondria as amaster fuel input undergirding the citric acid cycle carbon
ﬂux [47]. In addition, pyruvate is critical for mitochondrial ATP genera-
tion and for driving several major biosynthetic pathways intersecting
the citric acid cycle [47]. Pyruvate is also converted to acetyl-CoA by py-
ruvate dehydrogenase complex (PDH), and to oxaloacetate by pyruvate
carboxylase (Fig. 1). In this study, serum levels of pyruvate in BD pa-
tients were signiﬁcantly higher than those of healthy controls, while
serum levels of acetyl-CoA and oxaloacetate were not altered in BD pa-
tients. We recently found that CSF levels of pyruvate were higher in BD
patients than controls, even though the logistic regression analysis did
not reach to statistical signiﬁcance [Table S2 in 31]. Although the rea-
sons underlying increased pyruvate levels in BD patients are currently
unknown, it is likely that increased pyruvate levels plays a role in the
pathogenesis of BD. Since pyruvate supplies energy to living cellsFig. 2. A receiver-operating characteristics (ROC) curve and area under the curve (AUC) In
this model, after cross-validation testing using the jack-knife procedure, the model's
sensitivity was 85.2% and speciﬁcity was 76.9%. The Hosmer–Lemeshow goodness-of-ﬁt
statistic (the internal validation of the logistic regression model) was 3.6123 with 8 DF
(P = 0.8903), indicating a good ﬁt of the model.through the citric acid cycle, abnormality in the citric acid cycle in the
mitochondria might play a role in the pathogenesis of BD. It was recent-
ly reported that pyruvate was increased in serum and CSF from patients
with ASD, suggesting a possible mitochondrial dysfunction also in ASD
[48]. The precise mechanisms underlying pyruvate pathway alterations
in psychiatric disorders, including BD, needs to be further explored.
BD patients had higher serum levels of α-ketoglutarate than con-
trols. α-Ketoglutarate (2-oxoglutarate) is a key metabolite in the citric
acid cycle, but also an obligatory substrate for 2-oxoglutarate-
dependent dioxygenases (2-OGDO) (Fig. 1). The 2-OGDO enzyme fam-
ily includes the major enzymes of DNA and histone methylation [49]. It
is possible that altered α-ketoglutarate levels in BD lead to epigenetic
changes. Epigenetic modiﬁcations have been suggested to play an im-
portant role in the pathogenesis of a number of psychiatric disorders in-
cluding BD [50,51]. However, serum levels of α-ketoglutarate in rats
were signiﬁcantly increased after chronic Li (but not VPA) treatment.
It is therefore possible that Li medication may affect serum levels of α-
ketoglutarate in BDpatients despite that Limedicationwas not associat-
ed with serum levels of α-ketoglutarate in BD patients.
Recently, we reported that CSF levels of isocitrate were signiﬁcantly
higher in BD patients than in healthy control, and that the expression of
the isocitrate dehydrogenase (IDH) subtype IDH3A was lower in BD
postmortem brain samples than in control samples [31]. These ﬁndings
supported the mitochondrial dysfunction hypothesis in BD. However,
we did not ﬁnd alteration in the serum levels of isocitrate in the same
BD patients (Table 2). Thus, these changesmight be speciﬁc for the cen-
tral nervous system and not discernible in peripheral samples.
N-acetylglutamate is biosynthesized from glutamic acid (glutamate)
and acetyl-CoA by the enzyme N-acetylglutamate synthase
(NAGS)(Fig. 1). Mammalian NAGS is found primarily in the mitochon-
drial matrix of cells of the liver and intestines. N-acetylglutamate is
also known to activate carbamoyl phosphate synthetase (CPSI) in the
mitochondrial matrix of urea cycle (Fig. 1)[52,53]. In this study, we
found increased serum levels of N-acetylglutamate in BD patients.
Given the crucial role of N-acetylglutamate in the mitochondrial matrix
of cells, it is likely that an alteration in theN-acetylglutamate levels may
cause mitochondrial dysfunction, supporting a mitochondrial dysfunc-
tion hypothesis in BD. In CSF, however, we have previously found that
N-acetylglutamate is under the detection limit [31]. Therefore, it is un-
known whether N-acetylglutamate levels in the brain are altered in
BD patients.
Arginine is a conditionally essential amino acid for adult mammals.
This amino acid is not only metabolically interconvertible with the
amino acids proline and glutamate, but also it serves as a precursor for
the biosynthesis of proteins, creatine, polyamine, nitric oxide (NO),
agmatine, and urea. Arginine is mainly metabolized by the enzymes, ar-
ginase and NO synthase (NOS) to produce urea and L-ornithine, and NO
and citrulline, respectively (Fig. 1)[54,55]. In this study, we found that
serum levels of arginine in BD patients were signiﬁcantly higher than
in healthy controls, suggesting an abnormality in the urea cycle (or argi-
nine metabolism) in BD. We also found that serum levels of arginine
were associated with anxiolytic and antipsychotic medications. By con-
trast, we previously found that CSF levels of arginine did not differ be-
tween BD patients and healthy controls [31]. One previous study
showed that NOS activity in the platelets from BD patients (n = 28)
was signiﬁcantly lower than that of healthy controls (n= 10), suggest-
ing an impaired NO generation in BD patients [56]. A meta-analysis
showed that NO levels were altered in patients with BD [57]. Taken to-
gether, the arginine-NO pathwaymay play a role in the pathogenesis of
BD [58].
In the present study, we found that serum levels of total serine (L-
serine and D-serine)were signiﬁcantly lower in BD patients than in con-
trols, which is consistent with a recent paper of ours [26]. Our metabo-
lomics analysis did not distinguish the two enantiomers of serine,
although moderate levels of D-serine are known to exist in the human
blood [59,60]. Whereas serum levels of D-serine were higher in BD
157N. Yoshimi et al. / BBA Clinical 5 (2016) 151–158patients, serum levels of L-serine were lower in BD patients than con-
trols [26], thus suggesting an aberrant serinemetabolism in BDpatients.
Interestingly, we reported the opposite pattern in schizophrenia, with
increased L-serine and decreased D-serine serum levels [59,60]. The lat-
ter ﬁndings suggest that hypofunctioning NMDA receptors in schizo-
phrenia may be due to decreased D-serine levels [61,62]. Serum level
of total serine, including both L-serine and D-serine, signiﬁcantly de-
creased in BD patients (this study) although both enantiomers of serine
in depressed patients were higher than those on healthy subjects [63].
Considering the different roles of NMDA receptor neurotransmission
in the pathogenesis of schizophrenia and BD, measurements of serine
enantiomers (D- and L-serine) may represent diagnostic peripheral bio-
markers for these disorders [64]. Serine hydroxymethyltransferase 1 is
an enzyme in the reversible interconversion between glycine and L-ser-
ine. L-serine is also synthesized from 3-phosphoglycerate by 3-
phosphoglycerate dehydrogenase, and D-serine is synthesized from L-
serine by serine racemase and is metabolized by D-amino acid oxidase
[62]. Taken together, further studies on the role of biosynthesis andme-
tabolism of serine in BD are warranted.
This is the ﬁrst report showing decreased levels of β-alanine in BD
patients. A previous study found that CSF levels of β-alanine were not
altered in BD [31]. β-alanine is a naturally occurring non-essential
amino acid.β-alanine can be releasedduring thebreakdownof histidine
dipeptide, such as carnosine or anserine. Or it can be formed as a sec-
ondary byproduct of a reaction that converts L-alanine to pyruvate. In
addition, β-alanine can be produced during digestion, when intestinal
microbes remove a carbon atom from L-aspartate, releasing both β-
alanine and carbon dioxide (Fig. 1). The precisemechanisms underlying
the role of β-alanine synthesis/metabolism in the pathogenesis of BD
are currently unknown. Supplementation of β-alanine has been widely
used as the nutrition in sports [65,66]. Speculatively, it would be inter-
esting to examinewhether β-alanine supplementation can affect symp-
toms in BD patients.
There are some limitations to this study. First, only male subjects
were enrolled in this study. There are some reports showing gender dif-
ferences in the treatment of BD patients [67]. It remains to be examined
whether serum levels of thesemetabolites are also altered in female BD
patients. Second, it cannot be excluded that long-termmedication with
mood stabilizers, antidepressants, and antipsychotics may affect serum
levels of metabolites even though a 4-week treatment with Li or VPA
did not alter serum levels of metabolites (except α-ketoglutarate) in
rats. Therefore, further studies using a larger sample size of
medication-free patients will be needed.
5. Conclusion
The metabolomics analyses showed alterations in the serum levels
of pyruvate, N-acetylglutamic acid, β-alanine, serine and arginine in
BD patients, suggesting that abnormalities in the citric acid cycle, the
urea cycle, and the amino acid metabolism may play a role in the path-
ogenesis of BD. It is possible that these metabolites could serve as pe-
ripheral biomarkers for BD, although further studies using a larger
sample size are needed to conﬁrm the feasibility.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2016.03.008.
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